Skip to main content

Table 2 Mean differences of Liver enzymes and hematological parameters before and after

From: Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial

VariablesGroup*Mean ± SDVsMean±SDP-Value
Aspartate Aminotransferase
U/L
Baseline VS 24th Week157.06 ± 48.71Vs 20.17 ± 7.700.08
234.5 ± 25.27 Vs 21.61 ± 8.230.07
Alanine Aminotransferase
U/L
Baseline VS 24th Week150.89 ± 44.08 Vs 20.78 ± 10.810.02
240.5 ± 34.85 Vs 22.28 ± 11.920.06
Hemoglobin
g/dl
Baseline VS 24th Week110.53 ± 1.61 Vs 10.31 ± 1.690.70
211.51 ± 1.14 Vs 10.02 ± 1.7120.002
White Blood Cells
×103/mm3
Baseline VS 24th Week16.33 ± 1.94 Vs 5.78 ± 1.160.37
26.44 ± 1.91 Vs 6.61 ± 1.640.78
Platelets
×103/mm3
Baseline VS 24th Week1163.27 ± 65.90Vs 172.94 ± 62.740.61
2175.44 ± 40.11 Vs 184.89 ± 53.820.58
Paired t-test was used to assess the significance
  1. Treatment in Group 1 & Group 2 Patients (Per-Protocol Population)
  2. * Patient Treatment Groups:
  3. Group 1: Daily Daclatasvir + Sofosbuvir,
  4. Group 2: Daily Daclatasvir + 3 times/week Sofosbuvir